Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Completed × Abituzumab × Clear all

Phase

Phase 1 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1

Interventions

Cyclophosphamide 142 Gemcitabine 128 Paclitaxel 124 Radiotherapy 118 Carboplatin 111 Cisplatin 110 pembrolizumab 106 Nivolumab 106 Docetaxel 90 Rituximab 86 Lenalidomide 77 Dexamethasone 76 Cytarabine 69 Bevacizumab 65 Fluorouracil 63 Etoposide 63 Oxaliplatin 62 Filgrastim 59 Peripheral Blood Stem Cell Transplantation 58 Everolimus 58 Capecitabine 58 fludarabine phosphate 57 Doxorubicin 56 Temozolomide 55 Prednisone 54 Irinotecan 53 Cetuximab 50 fludarabine 49 Ipilimumab 48 Erlotinib Hydrochloride 48

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01008475 2016-03-30

POSEIDON

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed

232 enrolled 20 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡